Christian Hartinger
Christian Hartinger
Professor of Chemistry, University of Auckland
Verified email at - Homepage
Cited by
Cited by
From bench to bedside–preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis (1H-indazole) ruthenate (III)](KP1019 or FFC14A)
CG Hartinger, S Zorbas-Seifried, MA Jakupec, B Kynast, H Zorbas, ...
Journal of inorganic biochemistry 100 (5-6), 891-904, 2006
Bioorganometallic chemistry—from teaching paradigms to medicinal applications
CG Hartinger, PJ Dyson
Chemical Society Reviews 38 (2), 391-401, 2009
KP1019, a new redox‐active anticancer agent–Preclinical development and results of a clinical phase I study in tumor patients
CG Hartinger, MA Jakupec, S Zorbas‐Seifried, M Groessl, A Egger, ...
Chemistry & biodiversity 5 (10), 2140-2155, 2008
Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology
AR Timerbaev, CG Hartinger, SS Aleksenko, BK Keppler
Chemical reviews 106 (6), 2224-2248, 2006
Antitumour metal compounds: more than theme and variations
MA Jakupec, M Galanski, VB Arion, CG Hartinger, BK Keppler
Dalton transactions, 183-194, 2008
Challenges and opportunities in the development of organometallic anticancer drugs
CG Hartinger, N Metzler-Nolte, PJ Dyson
Organometallics 31 (16), 5677-5685, 2012
Anticancer activity of metal complexes: involvement of redox processes
U Jungwirth, CR Kowol, BK Keppler, CG Hartinger, W Berger, P Heffeter
Antioxidants & redox signaling 15 (4), 1085-1127, 2011
The development of RAPTA compounds for the treatment of tumors
BS Murray, MV Babak, CG Hartinger, PJ Dyson
Coordination Chemistry Reviews 306, 86-114, 2016
Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium (II)− arene compounds
A Casini, C Gabbiani, F Sorrentino, MP Rigobello, A Bindoli, TJ Geldbach, ...
Journal of medicinal chemistry 51 (21), 6773-6781, 2008
The ruthenium (II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways
S Chatterjee, S Kundu, A Bhattacharyya, CG Hartinger, PJ Dyson
JBIC Journal of Biological Inorganic Chemistry 13 (7), 1149-1155, 2008
Gold (III) compounds as anticancer agents: relevance of gold–protein interactions for their mechanism of action
A Casini, C Hartinger, C Gabbiani, E Mini, PJ Dyson, BK Keppler, ...
Journal of inorganic biochemistry 102 (3), 564-575, 2008
Structure–activity relationships for ruthenium and osmium anticancer agents–towards clinical development
SM Meier-Menches, C Gerner, W Berger, CG Hartinger, BK Keppler
Chemical Society Reviews 47 (3), 909-928, 2018
Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy
M Pongratz, P Schluga, MA Jakupec, VB Arion, CG Hartinger, G Allmaier, ...
Journal of Analytical Atomic Spectrometry 19 (1), 46-51, 2004
Resistance against novel anticancer metal compounds: differences and similarities
P Heffeter, U Jungwirth, M Jakupec, C Hartinger, M Galanski, L Elbling, ...
Drug resistance updates 11 (1-2), 1-16, 2008
Structure−Activity Relationships for NAMI-A-type Complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = Imidazole, Indazole, 1,2,4-Triazole, 4-Amino-1,2,4 …
M Groessl, E Reisner, CG Hartinger, R Eichinger, O Semenova, ...
Journal of medicinal chemistry 50 (9), 2185-2193, 2007
Opening the lid on piano-stool complexes: an account of ruthenium (II)–arene complexes with medicinal applications
AA Nazarov, CG Hartinger, PJ Dyson
Journal of Organometallic Chemistry 751, 251-260, 2014
Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study
F Lentz, A Drescher, A Lindauer, M Henke, RA Hilger, CG Hartinger, ...
Anti-cancer drugs 20 (2), 97-103, 2009
Redox behavior of tumor-inhibiting ruthenium (III) complexes and effects of physiological reductants on their binding to GMP
P Schluga, CG Hartinger, A Egger, E Reisner, M Galanski, MA Jakupec, ...
Dalton transactions, 1796-1802, 2006
Influence of the Spacer Length on the in Vitro Anticancer Activity of Dinuclear Ruthenium−Arene Compounds
MG Mendoza-Ferri, CG Hartinger, RE Eichinger, N Stolyarova, K Severin, ...
Organometallics 27 (11), 2405-2407, 2008
Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential
MA Jakupec, E Reisner, A Eichinger, M Pongratz, VB Arion, M Galanski, ...
Journal of medicinal chemistry 48 (8), 2831-2837, 2005
The system can't perform the operation now. Try again later.
Articles 1–20